INSIGHTS
-
FDA Expands Addyi Approval to Treat Postmenopausal Libido – What It Means and What to Know
Low sexual desire after menopause is common, and on December 15, 2025 the FDA expanded the label for Addyi (flibanserin) to include some postmenopausal women. This is a notable change: Addyi was first approved in 2015 for certain premenopausal women, and the new decision gives doctors another FDA‑cleared option for women under 65 who meet
-
Second Measles Surge of 2025: Why South Carolina’s Outbreak Is Accelerating and What You Need to Know
Measles is back in the headlines. After a major outbreak earlier this year, the United States is now seeing a second surge of measles cases, and one of the fastest-growing clusters is in South Carolina’s Upstate region. This post explains, in plain language, what’s happening, why it matters, and what you can do to protect
-
Coping with COPD: medications like tiotropium, how well they work, and the trade‑offs to expect
Living with COPD can feel like your lungs are always “on the edge.” The good news is there are medications that can open airways, reduce flare‑ups (exacerbations), and make daily life more manageable. This guide focuses on tiotropium (a common once‑daily inhaler) and similar treatments, explaining how they work, what studies say about benefits, and
-
FDA Approves Breyanzi for Relapsed or Refractory Marginal Zone Lymphoma
The U.S. Food and Drug Administration approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who have already tried at least two prior systemic therapies. This approval expands the list of cancers for which Breyanzi is authorized and gives patients a new option when other treatments have failed. In plain language: what is
-
FDA Approves Armlupeg – New Pegfilgrastim Biosimilar
The U.S. Food and Drug Administration has approved Armlupeg™ (pegfilgrastim‑unne) as a biosimilar to Neulasta® (pegfilgrastim) for decreasing the incidence of infection manifested by febrile neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive chemotherapy, and for increasing survival after acute exposure to myelosuppressive radiation. This approval adds another pegfilgrastim biosimilar to the U.S. market and
-
FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy — Itvisma (onasemnogene abeparvovec‑brve)
Background and mechanism Spinal muscular atrophy (SMA) is an autosomal‑recessive neurodegenerative disorder caused by loss‑of‑function mutations in the SMN1 gene, resulting in reduced survival motor neuron (SMN) protein, progressive motor neuron loss, and muscle atrophy. Gene‑replacement therapy using adeno‑associated virus (AAV) vectors delivers a functional copy of SMN1 to motor neurons, restoring SMN protein expression
-
Acid Indigestion and GERD: Causes, Risks, and Effective Treatments
Acid indigestion and gastroesophageal reflux disease (GERD) are among the most prevalent gastrointestinal disorders globally, affecting millions of individuals and imposing significant clinical, economic, and quality-of-life burdens. Acid indigestion, often referred to as heartburn or dyspepsia, is characterized by a burning sensation in the chest or upper abdomen, frequently after meals. GERD, a chronic and
-
FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review
The U.S. Food and Drug Administration (FDA) has approved a reformulated ranitidine tablet after a comprehensive safety review addressing prior concerns about N‑nitrosodimethylamine (NDMA) impurity formation; the approval includes updated storage and handling requirements to mitigate impurity risk and preserve product stability. Background and regulatory context Ranitidine, an H2‑receptor antagonist widely used for gastroesophageal reflux
-
Big Holiday Meals and Hidden Health Risks
Large holiday meals are a cherished tradition, but research shows they can also be dangerous. From cardiovascular emergencies to foodborne illness, the risks of overindulgence are real – and often underestimated. Heart Attacks Surge During the Holidays Scientific studies confirm that cardiac deaths increase by 5–15% between Thanksgiving and New Year’s Day. The American Heart
-
CDC’s Shift on Vaccine and Autism Stance Nov 2025
Has the CDC Quietly Changed Its Stance on Vaccines and Autism? On November 19–20, 2025, the U.S. Centers for Disease Control and Prevention (CDC) made a significant and abrupt revision to its public-facing guidance on the relationship between vaccines and autism. This change, which replaced longstanding language unequivocally stating that vaccines do not cause autism